Chlorthalidone
Chlorthalidone is a thiazide-like diuretic taken by mouth. The US label read, for Thalitone, lists two uses: the treatment of hypertension, to lower blood pressure, and, in adults, adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome. Thalitone is one brand; other chlorthalidone tablets have their own labels, which were not read.
Also called Thalitone · Chlortalidone
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 2409; UNII Q0MQD1073Q. MeSH descriptor D002752 is Chlorthalidone. Class: Thiazide-like Diuretic (FDA established pharmacologic class, RxClass). The label read is the THALITONE (chlorthalidone) tablets, Casper Pharma LLC label, effective 2026-06-25 in openFDA (application NDA019574). Other chlorthalidone labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 5 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 4 | 2 | 1 | 1 | 4 |
| All phases | 3 | 1 | 1 | 5 |
Conditions these trials study
Sponsors with the most trials
- Cambridge University Hospitals NHS Foundation Trust
- Indiana University
- Novartis
- University Hospital Birmingham
- University of Florida
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context People for whom the US label of chlorthalidone (Thalitone) lists an indication: hypertension, edema (including edema of heart failure)
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. Only the edema sentence says adults; the hypertension passage read does not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Only the edema sentence says adults; the hypertension passage read does not state an age range
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with hypertension
- Adults with edema associated with heart failure, cirrhosis of the liver, or renal disease including nephrotic syndrome
- Excluded
- None stated
The US label of THALITONE (chlorthalidone), in the Casper Pharma LLC version dated 2026-06-25 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, and, in adults, as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.
Applies to Recipient not specified People for whom the US label of chlorthalidone (Thalitone) lists an indication: hypertension, edema (including edema of heart failure)
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-06-25
- Source state
- Current
- Version fingerprint
b8ddb25b1964616c0cf70118ed5dcb0d5be237fbde35a857491f11293305ae5a- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260625.
- Retrieved
- Source effective date
- 2026-06-25
- Source state
- Current
- Version fingerprint
b8ddb25b1964616c0cf70118ed5dcb0d5be237fbde35a857491f11293305ae5a- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
COMBIPRES
No label from the application holder was found in the openFDA label dataset for application NDA017503. This page does not show another labeler's label in its place.
EDARBYCLOR
No label from the application holder was found in the openFDA label dataset for application NDA202331. This page does not show another labeler's label in its place.
HEMICLOR
No label from the application holder was found in the openFDA label dataset for application NDA218647. This page does not show another labeler's label in its place.
HYGROTON
No label from the application holder was found in the openFDA label dataset for application NDA012283. This page does not show another labeler's label in its place.
KERLEDEX
No label from the application holder was found in the openFDA label dataset for application NDA019807. This page does not show another labeler's label in its place.
REGROTON
No label from the application holder was found in the openFDA label dataset for application NDA015103. This page does not show another labeler's label in its place.
TENORETIC 100
No label from the application holder was found in the openFDA label dataset for application NDA018760. This page does not show another labeler's label in its place.
THALITONE
No label from the application holder was found in the openFDA label dataset for application NDA019574. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of chlorthalidone (Thalitone) lists an indication: hypertension, edema (including edema of heart failure)
The US label of THALITONE (chlorthalidone), in the Casper Pharma LLC version dated 2026-06-25 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, and, in adults, as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists adjunctive therapy, in adults, in edema associated with heart failure as an indication: Heart failure
Applies to Recipient not specified People for whom the US label of chlorthalidone (Thalitone) lists an indication: hypertension, edema (including edema of heart failure)
The US label of THALITONE (chlorthalidone), in the Casper Pharma LLC version dated 2026-06-25 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, and, in adults, as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 8
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 5
Record details
- Record id
cardio:chlorthalidone- Content hash
62ed722b4a7532805391080ba3b7e088911c4c70dc75b684940b0c30f22e8ed6